42 completed, 24 recruiting, 22 unknown, 11 terminated. 30 Phase 2, 21 Not applicable, 18 Phase 3, 10 Phase 4, 8 Phase 1.
Follow Glomerulonephritis, Membranous: new trials by email Literature Review of Glomerulonephritis, Membranous trials Research Report on Glomerulonephritis, Membranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 12 | 2026-10-31 | 2026-09-10 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous | Phase 3 | Recruiting | Amgen | 159 | 2026-10-01 | 2026-10-01 |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy Membranous Nephropathy, Nephrotic Syndrome | Not yet recruiting | Assiut University | 128 | 2026-08-20 | 2026-09-02 | |
| Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy CD19 CAR-γδ T cell - Membranous Nephropathy, Lupus Nephritis (LN) | Early Phase 1 | Not yet recruiting | Air Force Military Medical University, China | 15 | 2026-05-01 | 2026-04-16 |
| Omics of Rituximab-resistance Multi-omics Analysis, Sample collection - Membranous Nephropathy | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 120 | 2026-04-01 | 2026-02-18 | |
| Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing - Refractory Idiopathic Membranous Nephropathy | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | 18 | 2026-02-28 | 2026-02-20 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment. - Refractory Membranous Nephropathy | Phase 1 | Recruiting | The First Affiliated Hospital of Air Force Medicial University | 5 | 2025-12-08 | 2025-12-24 |
| Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis ANCA Associated Vasculitis, Extramembranous Glomerulopathy | Recruiting | Assistance Publique - Hôpitaux de Paris | 146 | 2025-11-03 | 2026-06-30 | |
| Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study Obinutuzumab administration - Membranous Nephropathy - PLA2R Induced | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 20 | 2025-10-01 | 2026-01-06 |
| Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy Flow-cytometry tetramer-based antigen-bait assay - Membranous Nephropathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 48 | 2025-09-22 | 2026-03-20 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01 - Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Shanghai Henlius Biotech | 24 | 2025-08-05 | 2025-11-18 |
| Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) RiTUXimab Injection - Membranous Nephropathy | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nice | 120 | 2025-02-04 | 2026-06-22 |
| IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients IM19 chimeric antigen receptor T cell injection - IgA Nephropathy, Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-12-13 | 2024-11-26 |
| An Outcome Analysis of Primary Membranous Nephropathy Membranous Nephropathy | Recruiting | Mario Negri Institute for Pharmacological Research | 500 | 2024-11-29 | 2026-03-23 | |
| Circulating Factors in Nephrotic Syndrome Observation - Nephrotic Syndrome, Membranous Nephropathy | Not yet recruiting | Iain Bressendorff | 104 | 2024-04-01 | 2024-03-19 |
Showing 20 of 114. Sign in to see all of them.
Nephrotic Syndrome (21) · Glomerulonephritis, IGA (18) · Glomerulosclerosis, Focal Segmental (16) · Nephrosis, Lipoid (15) · Glomerulonephritis (11) · Proteinuria (11) · Kidney Diseases (10) · Lupus Nephritis (9) · Diabetic Nephropathies (7) · Macular dystrophy, corneal type 1 (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Glomerulonephritis, Membranoproliferative (3) · Lupus Erythematosus, Systemic (3) · Nephritis, Hereditary (3)
Female Urogenital Diseases (114) · Female Urogenital Diseases and Pregnancy Complications (114) · Immune System Diseases (114) · Male Urogenital Diseases (114) · Nephritis (114) · Urogenital Diseases (114) · Autoimmune Diseases (113) · Urologic Diseases (113) · Kidney Diseases (104) · Glomerulonephritis (103) · Nephrosis (28) · Pathological Conditions, Signs and Symptoms (19) · Skin and Connective Tissue Diseases (15) · Connective Tissue Diseases (13) · Signs and Symptoms (13)
Rituximab (19) · Tacrolimus (13) · Cyclophosphamide (8) · Cyclosporine (7) · Prednisone (7) · Glucocorticoids (5) · Mycophenolic Acid (5) · Adrenocorticotropic Hormone (3) · Blood Specimen Collection (3) · Methylprednisolone (3) · Prednisolone (3) · Steroids (3) · belimumab (3) · felzartamab (3) · obinutuzumab (3)
Qianfoshan Hospital (8) · Centre Hospitalier Universitaire de Nice (7) · Mario Negri Institute for Pharmacological Research (6) · Mayo Clinic (5) · Beijing Friendship Hospital (4) · Radboud University Medical Center (4) · Assistance Publique - Hôpitaux de Paris (3) · Guangdong Provincial People's Hospital (3) · Istanbul University (3) · University of Michigan (3) · Columbia University (2) · GlaxoSmithKline (2) · HI-Bio, A Biogen Company (2) · Hospital Authority, Hong Kong (2) · Nanjing University School of Medicine (2)
China (35) · United States (26) · France (14) · Italy (10) · United Kingdom (8) · Netherlands (7) · Canada (5) · South Korea (5) · Spain (5) · Australia (4) · Turkey (Türkiye) (4) · Germany (3) · Czechia (2) · Greece (2) · Hong Kong (2)
Fernando C. Fervenza, M.D., Ph.D. (3) · Daniel TM Chan, Prof (2) · Giuseppe Remuzzi, M.D. (2) · Giuseppe Remuzzi, MD (2) · Halil Yazici, MD (2) · Matthias Kretzler, MD (2) · Safak Mirioglu, MD (2) · Zhihong Liu, Master (2) · Anne-Els Van de Logt, M.D., PhD (1)
PMID 34778952, PMID 31340979, PMID 40465397, PMID 16164651, PMID 17377504, PMID 17660026, PMID 19666912, PMID 20220333, PMID 2023605, PMID 2142748, PMID 21677438, PMID 22371643, PMID 22722778, PMID 22995802, PMID 23150796, PMID 23449768, PMID 23689577, PMID 24009220, PMID 24189358, PMID 24375637, PMID 24707402, PMID 25457107, PMID 26087670, PMID 26562836, PMID 26577187, PMID 26589142, PMID 27352623, PMID 29441742, PMID 31269364, PMID 31492152, PMID 31806605, PMID 32231244, PMID 32842999, PMID 32903623, PMID 33311560, PMID 33649098, PMID 34060483, PMID 34721403, PMID 34796395, PMID 35224732, PMID 35672893, PMID 36283759, PMID 36821613, PMID 37036696, PMID 39513526, PMID 39661388, PMID 39899371, PMID 40180405, PMID 40478760, PMID 40581835
2025 (2), R01DK141114 (2), U54DK083912 (2), 2008 (1), 2019 (1), K23DK093556 (1)